FAQ

BL 3459

Known as: BL-3459 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1975-1981
01219751981

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1981
1981
Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro.
Collegan-induced platelet aggregation in mouse citrated platelet-rich (PRP) was associated with 5-hydroxytryptamine (5-HT… (More)
Is this relevant?
1981
1981
Comparison of sulfinpyrazone and BL-3459 with S - 20344, a potent new antithrombotic agent.
 
Is this relevant?
1979
1979
Antiplatelet drugs and the generalized Shwartzman reaction in the pregnant rat.
Several antiplatelet drugs (aspirin, sulfinpyrazone, hydroxychloroquine, dipyridamole, BL-3459, pyridinolcarbamate) were assayed… (More)
Is this relevant?
1976
1976
The effect of a potent inhibitor of platelet aggregation, BL-3459, on adrenaline-induced myocardial necrosis in beagle dogs.
The effect of a potent inhibitor of platelet aggregation, BL-3459, on adrenaline-induced myocardial necrosis was investigated in… (More)
Is this relevant?
1975
1975
Pharmacology of a potent, new antithrombotic agent, 6-methyl-1,2,3,5-tetrahydroimidazo[2, 1-b] quinazolin-2-one hydrochloride monohydrate.
The effect of 6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b] quinazolin-2-one hydrochloride monohydrate (BL-3459) on platelet function… (More)
Is this relevant?